Last reviewed 2026-05-19 · How we verify

PRGN-3006 T Cells

Precigen, Inc · Phase 1 active Small molecule ✓ Verified May 2026

PRGN-3006 T Cells is a Small molecule drug developed by Precigen, Inc. It is currently in Phase 1 development.

PRGN-3006 T Cells are being studied in clinical trials for the treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes. The mechanism of PRGN-3006 T Cells is not specified as a small molecule, as ClinicalTrials.gov does not provide information on the mechanism and ChEMBL lists PRGN-3006 as a small molecule, but it is described as T Cells in ClinicalTrials.gov.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	PRGN-3006 T Cells
Sponsor	Precigen, Inc
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

PRGN-3006 T Cells CI brief — competitive landscape report
PRGN-3006 T Cells updates RSS · CI watch RSS
Precigen, Inc portfolio CI

Frequently asked questions about PRGN-3006 T Cells

What is PRGN-3006 T Cells?

PRGN-3006 T Cells is a Small molecule drug developed by Precigen, Inc.

Who makes PRGN-3006 T Cells?

PRGN-3006 T Cells is developed by Precigen, Inc (see full Precigen, Inc pipeline at /company/precigen-inc).

What development phase is PRGN-3006 T Cells in?

PRGN-3006 T Cells is in Phase 1.

Manufacturer: Precigen, Inc — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing